OPTN protects retinal ganglion cells and ameliorates neuroinflammation in optic neuropathies

Qinglong Wang, Yiqi Wang, Yong‐hui Jiang, Ryan Donahue, Guangmei Cao, Wensheng Yan, Hong Guo, Jin Hao, Yi Lu, Qianbin Wang, Feng TianbioRxiv 2025 · DOI

TL;DR

This study reveals that the protein Optineurin (OPTN) plays a critical neuroprotective role in the retina, preventing chronic neuroinflammation and the death of retinal ganglion cells (RGCs). Loss of OPTN function exacerbates neuroinflammation and RGC degeneration, suggesting a shared mechanism in different types of glaucoma, and highlights the OPTN-NPY pathway as a potential therapeutic target.

What Problem Does This Paper Address?

Glaucoma is a leading cause of irreversible vision loss, characterized by the degeneration of retinal ganglion cells (RGCs) and their axons in the optic nerve. While elevated intraocular pressure (IOP) is a major risk factor, a significant portion of glaucoma patients, particularly those with normal-tension glaucoma (NTG), experience vision loss despite normal IOP. This suggests that IOP-independent mechanisms, such as neuroinflammation, play a crucial role in RGC degeneration. Optineurin (OPTN) is a protein implicated in various diseases, including glaucoma, but its specific role in glaucoma pathogenesis, especially the impact of its loss-of-function, remained unclear. This paper investigates how OPTN dysfunction contributes to chronic neuroinflammation and RGC death, aiming to uncover shared pathological mechanisms in different glaucoma subtypes and identify potential therapeutic targets.

Methods

The researchers utilized a combination of experimental techniques and bioinformatics analyses:

  • Optineurin (OPTN) knockout mouse model: They created a conditional knockout of OPTN in retinal cells using AAV2-Cre viral vectors in OPTN-floxed mice. This allowed for targeted investigation of OPTN's role in the retina.
  • Viscobead injection model: To mimic high intraocular pressure (IOP) conditions, they employed a viscobead injection method to induce ocular hypertension in mice.
  • Immunohistochemistry (IHC): This technique was used to visualize and quantify specific cell types and markers in retinal and optic nerve tissues, including RGCs (RBPMS), astrocytes (GFAP), and microglia (Iba1, CD68).
  • Intraocular Pressure (IOP) Measurement: IOP was measured using a TonoLab tonometer to assess the effect of the viscobead injection and OPTN knockout on IOP.
  • Bioinformatic Analysis: Single-cell RNA sequencing (scRNA-seq) data from human and mouse retinas were analyzed to identify differentially expressed genes and pathways related to OPTN expression and RGC vulnerability. This included analyzing data from both healthy and glaucomatous eyes.

Datasets

  • Mouse scRNA-seq data: Used to analyze OPTN expression in resilient vs. susceptible RGCs and identify differentially expressed genes.
  • Human POAG patient data: Used for bioinformatic analysis to assess the downregulation of OPTN, NPY, and FAM19A4 in glaucomatous degeneration.
  • Publicly available datasets: Mentioned for further analysis of scRNA-seq data (GSE137398 from Human Cell Atlas).

Key Insights and Ideas

  • OPTN is a critical neuroprotective factor in the retina: Loss of OPTN function directly leads to chronic RGC death, even without elevated IOP.
  • OPTN deficiency fuels neuroinflammation: The absence of OPTN triggers sustained activation of microglia and short-term astrogliosis, contributing to RGC damage.
  • Shared mechanisms in glaucoma: The findings suggest that OPTN dysfunction and the resulting neuroinflammation are common pathological pathways in both normal-tension glaucoma (NTG) and high-tension glaucoma (HTG).
  • OPTN-NPY pathway is key: OPTN promotes the expression of Neuropeptide Y (NPY), which in turn suppresses CHOP-mediated neuroinflammation and protects RGCs. This highlights a novel neuroprotective signaling axis.
  • Therapeutic potential: The OPTN-NPY pathway, and specifically targeting CHOP-mediated neuroinflammation, presents a promising therapeutic avenue for glaucoma, especially for cases resistant to IOP-lowering treatments.

Key Results

  • OPTN knockout in mice led to progressive RGC loss over 1, 3, and 6 months post-injection, without affecting IOP.
  • OPTN loss induced short-term reactive astrogliosis and long-term microglia activation in the retina, which also extended to the optic nerve.
  • In a high IOP model (viscobead injection), OPTN knockout did not exacerbate RGC death, suggesting that OPTN deficiency and elevated IOP might affect overlapping vulnerable RGC populations.
  • Bioinformatic analysis revealed that OPTN is enriched in resilient RGCs and its expression increases after injury.
  • OPTN-expressing RGCs showed significantly higher expression of FAM19A4 and NPY.
  • Downregulation of OPTN in POAG patients was associated with reduced NPY and FAM19A4 expression.
  • OPTN knockout led to increased expression of CHOP, a pro-apoptotic gene, indicating its role in ER stress-mediated neuroinflammation.

Limitations and Future Work

  • RGC subtype susceptibility: The study acknowledges a limitation in not pinpointing the exact susceptibility of each RGC subtype to OPTN deficiency under different IOP conditions. Future single-cell transcriptomic analysis is suggested for this purpose.
  • Non-cell-autonomous effects: While the study focused on retinal OPTN knockout, the authors note that AAV2 can transduce other retinal cells (e.g., amacrine cells), making it difficult to entirely exclude non-cell-autonomous RGC death mechanisms.
  • Domain-specific mutations: The study used a C-terminus truncation of OPTN. The authors suggest it would be interesting to investigate if mutations in different domains of OPTN (e.g., N-terminal coiled-coil domain) lead to different pathological mechanisms.
  • Further investigation of binding partners: The role of other binding partners of the OPTN/TBK1 complex in neuroprotection or neurodegeneration warrants further investigation.
  • Broader therapeutic applications: The findings suggest that the OPTN-NPY pathway could be a target for other neurodegenerative diseases beyond glaucoma.

Summary updated

Abstract

Optineurin (OPTN) is a crucial component of the homeostatic pathway, playing a pivotal role in regulating a number of essential signaling pathways including NF-κB, interferon, autophagy, and vesicular trafficking. The dysfunction of OPTN has been implicated in the pathogenesis of several diseases, such as primary open angle glaucoma (POAG), amyotrophic lateral sclerosis (ALS), frontotemporal lobar dementia, and Paget’s disease of bone. Interestingly, mutations in OPTN are implicated as gain-of-function in glaucoma pathology and loss-of-function in ALS. However, the role of loss-of-function OPTN in glaucoma pathology remains unclear. Here, we demonstrate that OPTN dysfunction contributes to chronic neuroinflammation, leading to sustained RGC death, which may represent a shared pathological mechanism in both normal tension glaucoma (NTG) and high-tension glaucoma (HTG). Retinal conditioned OPTN knockout contributes to short-term astrogliosis and long-term microglia activation, with the propagation of microglia activation spreading to the optic nerve. Moreover, OPTN loss of function does not further exacerbate RGC death in the ocular hypertension mouse model induced by viscobead injection. Combined with the downregulation of OPTN in glaucoma patients, we have revealed an IOP-independent mechanism of glaucoma pathogenesis. Furthermore, we found that OPTN-driven NPY upregulation may suppress the CHOP-associated neurodegeneration. Our findings reveal a neuroprotective role for the OPTN-NPY signaling pathway, and its dysfunction promotes RGC loss in glaucoma pathology. The OPTN-NPY-mediated neuroinflammatory pathway provides a potential therapy for IOP-resistant glaucoma and highlights a druggable target for CHOP-associated neurodegeneration.
BibTeX
@misc{wang2025optn,
  author = {Qinglong Wang and Yiqi Wang and Yong‐hui Jiang and Ryan Donahue and Guangmei Cao and Wensheng Yan and Hong Guo and Jin Hao and Yi Lu and Qianbin Wang and Feng Tian},
  title = {{OPTN protects retinal ganglion cells and ameliorates neuroinflammation in optic neuropathies}},
  year = {2025},
  doi = {10.1101/2025.01.09.632264},
  howpublished = {bioRxiv},
}
Figure